Sign Out
Patients must be adequately supplemented with calcium and vitamin D.
A single dose should not exceed 4 mg as a single dose intravenous infusion and the duration of infusion should be no less than 15 minutes.
Adequately rehydrate patients with hypercalcemia of malignancy prior to administration of Zoledronic Acid for Injection and monitor electrolytes during treatment.
Renal toxicity may be greater in patients with renal impairment. Do not use doses greater than 4 mg.
Treatment in patients with severe renal impairment is not recommended. Monitor serum creatinine before each dose.
Zoledronic Acid should not be used during pregnancy. It can cause fetal harm.
Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant.
Osteonecrosis of the jaw has been reported. Preventive dental exams should be performed before starting Zoledronic Acid. Avoid invasive dental procedures.
Severe incapacitating bone, joint, and/or muscle pain may occur. Withhold future doses of Zoledronic Acid if severe symptoms occur.
Do not mix with calcium-containing infusion solutions.
Continue with Google